Cypress Capital Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.98M Sell
47,312
-1,115
-2% -$147K 0.56% 43
2026
Q1
$6.75M Sell
48,427
-159
-0.3% -$22.3K 0.76% 37
2025
Q4
$5.96M Sell
48,586
-18
-0% -$2.19K 0.67% 40
2025
Q3
$5.4M Buy
48,604
+71
+0.1% +$8.07K 0.65% 38
2025
Q2
$5.38M Buy
48,533
+551
+1% +$58.6K 0.67% 40
2025
Q1
$5.38M Sell
47,982
-1,129
-2% -$116K 0.7% 40
2024
Q4
$4.54M Sell
49,111
-1,173
-2% -$106K 0.56% 47
2024
Q3
$4.22M Sell
50,284
-635
-1% -$48.5K 0.47% 53
2024
Q2
$3.49M Sell
50,919
-89
-0.2% -$5.94K 0.42% 58
2024
Q1
$3.74M Sell
51,008
-399
-0.8% -$30.7K 0.45% 60
2023
Q4
$4.16M Sell
51,407
-4,850
-9% -$377K 0.54% 51
2023
Q3
$4.22M Sell
56,257
-1,802
-3% -$139K 0.61% 46
2023
Q2
$4.47M Sell
58,059
-3,371
-5% -$269K 0.65% 44
2023
Q1
$5.1M Sell
61,430
-12,256
-17% -$1.02M 0.78% 35
2022
Q4
$6.33M Sell
73,686
-89
-0.1% -$7.05K 0.95% 29
2022
Q3
$4.55M Buy
73,775
+982
+1% +$61.9K 0.76% 40
2022
Q2
$4.5M Buy
72,793
+7,445
+11% +$461K 0.69% 41
2022
Q1
$3.88M Buy
65,348
+12,484
+24% +$798K 0.48% 62
2021
Q4
$3.84M Buy
52,864
+9,527
+22% +$656K 0.48% 60
2021
Q3
$3.03M Sell
43,337
-964
-2% -$67.7K 0.41% 66
2021
Q2
$3.05M Sell
44,301
-313
-0.7% -$20.9K 0.41% 69
2021
Q1
$2.88M Buy
44,614
+951
+2% +$61.3K 0.41% 69
2020
Q4
$2.54M Sell
43,663
-2,076
-5% -$125K 0.38% 68
2020
Q3
$2.89M Sell
45,739
-9,603
-17% -$666K 0.48% 58
2020
Q2
$4.26M Buy
55,342
+7,759
+16% +$595K 0.78% 37
2020
Q1
$3.56M Buy
47,583
+3,738
+9% +$258K 0.82% 40
2019
Q4
$2.85M Sell
43,845
-1,530
-3% -$99.6K 0.51% 63
2019
Q3
$2.88M Sell
45,375
-928
-2% -$60.7K 0.55% 58
2019
Q2
$3.13M Buy
46,303
+1,717
+4% +$113K 0.62% 53
2019
Q1
$2.9M Sell
44,586
-3,365
-7% -$224K 0.59% 53
2018
Q4
$3M Sell
47,951
-2,882
-6% -$201K 0.69% 47
2018
Q3
$3.92M Buy
50,833
+10,014
+25% +$756K 0.74% 44
2018
Q2
$2.89M Sell
40,819
-2,980
-7% -$210K 0.6% 56
2018
Q1
$3.3M Buy
43,799
+2,621
+6% +$208K 0.69% 50
2017
Q4
$2.95M Sell
41,178
-1,067
-3% -$81K 0.61% 56
2017
Q3
$3.42M Buy
42,245
+500
+1% +$38.2K 0.73% 46
2017
Q2
$2.96M Buy
41,745
+25
+0.1% +$1.66K 0.65% 55
2017
Q1
$2.83M Sell
41,720
-725
-2% -$51K 0.66% 56
2016
Q4
$3.04M Buy
42,445
+296
+0.7% +$22K 0.72% 49
2016
Q3
$3.33M Sell
42,149
-5,716
-12% -$464K 0.8% 44
2016
Q2
$3.99M Sell
47,865
-4,075
-8% -$362K 0.93% 38
2016
Q1
$4.77M Sell
51,940
-3,069
-6% -$277K 1.17% 31
2015
Q4
$5.57M Sell
55,009
-3,480
-6% -$362K 1.34% 27
2015
Q3
$5.74M Buy
58,489
+1,945
+3% +$216K 1.42% 23
2015
Q2
$6.62M Sell
56,544
-675
-1% -$73.8K 1.52% 20
2015
Q1
$5.62M Buy
57,219
+7,037
+14% +$715K 1.28% 27
2014
Q4
$4.73M Sell
50,182
-4,943
-9% -$511K 1.1% 31
2014
Q3
$5.87M Sell
55,125
-530
-1% -$51.9K 1.39% 21
2014
Q2
$4.62M Buy
55,655
+2,295
+4% +$179K 1.08% 29
2014
Q1
$3.78M Buy
53,360
+4,150
+8% +$325K 0.93% 36
2013
Q4
$3.7M Sell
49,210
-3,200
-6% -$223K 0.91% 39
2013
Q3
$3.29M Sell
52,410
-400
-0.8% -$23.9K 0.81% 44
2013
Q2
$2.71M Buy
+52,810
New +$2.75M 0.57% 64

Other funds holding GILD

Cypress Capital Group's GILD Position: Q2 2026 in Review

Cypress Capital Group reduced its Gilead Sciences (GILD) stake by 2.3% in Q2 2026, selling an estimated $147K and leaving 47,312 shares worth $5.98M. The position accounts for 0.56% of the portfolio, ranked #43.

Cypress Capital Group first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.75M in Q1 2026. 1,755 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Cypress Capital Group held 47,312 shares of Gilead Sciences worth $5.98M as of Q2 2026.
  • Cypress Capital Group sold 1,115 Gilead Sciences shares in Q2 2026, an estimated $147K.
  • Gilead Sciences made up 0.56% of Cypress Capital Group's portfolio in Q2 2026, its #43 holding.
  • Cypress Capital Group first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Cypress Capital Group's Gilead Sciences position peaked at $6.75M in Q1 2026.
  • 1,755 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Cypress Capital Group's 13F filing for Q2 2026, filed 5 Aug 2026.